Indoco Remedies launches Brinzolamide Ophthalmic Suspension 1% in US

The US market size of this product is $184 million, according to IQVIA data as of December, 2020.

Commenting on this achievement, Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. said, "This first-to-market generic version of AZOPT (Brinzolamide Ophthalmic Suspension 1%, developed by Indoco) in the U.S. brings in an enormous opportunity to Indoco to serve the patients with a generic option. It also provides us immense satisfaction to be part of the journey in developing and securing approval from the US regulators for such Complex Generic products (ophthalmic suspensions), ensuring access to affordable and quality medicines."

Ms. Panandikar also added, "Indoco is vertically integrated for Brinzolamide API (manufactured at Patalganga site), which gives an edge to ensure continuity in commercial supplies."